Adagio Medical Explores Strategic Alternatives, Cuts 25 of Its 43 Jobs

Adagio Medical Holdings said on Sept. 23 that its board has started a formal process to explore strategic alternatives and that it is cutting its workforce to align costs with its prioritized programs, according to a company press release distributed by Business Wire, read via Finviz.

The Laguna Hills, California, company will reduce its staff by 25 of 43 full-time employees, effective the same day, according to a Form 8-K filed with the Securities and Exchange Commission. Adagio estimated it will incur about $1.3 million in cash expenditures, consisting primarily of one-time severance payments, benefits and related costs. The filing said the plan was adopted "to extend its capital resources" and that the company may incur other charges, including potential impairment charges it could not yet estimate.

What the review could lead to

Adagio said the alternatives it will explore may include, but are not limited to, an acquisition, merger, business combination or other transaction. "There can be no assurance that its exploration will result in Adagio pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all," the company said. It has not set a timetable and does not plan to disclose further developments unless it decides disclosure is appropriate or necessary.

As of June 30, 2026, Adagio had a preliminary unaudited total of about $7.7 million in cash, cash equivalents and investments in marketable securities, according to the release.

The 8-K also disclosed that, in connection with the review, Adagio notified holders of its 13% senior secured convertible notes that it would lower their conversion price for each date from Sept. 23 through Oct. 31, 2026, subject to extension, to an alternate price tied to recent trading in its stock.

The vCLAS application

Adagio develops catheter-based ultra-low temperature ablation technology, which it calls ULTA, for cardiac arrhythmias. Its lead product, the vCLAS Ventricular Ablation System, is CE marked and commercially available for monomorphic ventricular tachycardia in Europe and some other markets, but limited to investigational use in the United States, the company said.

In May 2026, Adagio submitted results of its FULCRUM-VT pivotal study to support a premarket approval application to the FDA for vCLAS. The headline of the company's release said it continues to advance that application while the board evaluates its options. Adagio is also developing a next-generation catheter, vCLAS Ultra, which it says is designed for faster procedures with a smaller and more flexible form factor.

The company did not disclose expected cost savings from the job cuts or an updated cash runway.